New research from the University of Pennsylvania suggests that increasing access to medical cannabis may support chronic pain patients in reducing their reliance on prescription opioid medications. This finding emerges amidst ongoing concerns regarding opioid-related overdose deaths, highlighting a potential harm-reduction strategy.
Researchers from the University of Pennsylvania’s Perelman School of Medicine noted, “Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm-reduction tool for some patients seeking to reduce reliance on higher-risk opioid medications.” This perspective underscores a shift in understanding the role of medical cannabis in pain management.
Examining Medical Cannabis and Opioid Reduction
The study, a prospective observational trial conducted at the Hospital of the University of Pennsylvania, followed 29 adult participants over five months. All participants had experienced chronic pain for a median of 11 years and were already taking opioid medications, having previously struggled to taper their use despite other treatments.
A distinctive aspect of this investigation was its focus on the impact of removing cost as a barrier to accessing medical cannabis. The researchers described their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.” Participants had previously identified cost as a significant obstacle to initiating medical cannabis therapy.
Recruited from a university-based outpatient chronic pain clinic, participants underwent monthly assessments using the Numeric Pain Rating Scale (NRS) to measure pain levels. Researchers also meticulously tracked daily opioid use, quantified in morphine milligram equivalents (MMEs).
Key Findings on Pain and Opioid Use
The study reported several notable outcomes:
- Seven patients, representing 24% of the cohort, were able to completely discontinue opioid therapy by the study’s conclusion. Five of these individuals achieved this by the second month.
- There was a statistically significant reduction in mean pain scores, which was sustained throughout the five-month study period.
- Mean daily opioid consumption decreased from a baseline of 46.8 MMEs/day to 16.2 MMEs/day at one month, remaining consistently low over the follow-up period. This represents an approximate reduction of 32 MMEs per day.
These findings, published in the Cureus Journal of Medical Science, suggest a potential for medical cannabis to support patients in managing chronic pain while concurrently reducing opioid intake.
Considerations and Future Research
While the results are encouraging, the study’s authors were careful to outline its limitations. They noted the small sample size, its derivation from a single clinical site, and the absence of a control group. Additionally, patients self-titrated their medical cannabis products, leading to variability in dosing and frequency of use, which means the findings are not standardised in this regard.
Despite these limitations, the researchers concluded that “when used under appropriate medical supervision, medical cannabis may represent an effective adjunctive strategy for reducing opioid use among patients receiving long-term opioid therapy.” This study adds to a growing body of literature, building on earlier research as previously reported by Hemp Gazette, that explores the potential role of medical cannabis in opioid reduction strategies.
The findings indicate that medical cannabis may be a useful adjunct therapy for managing chronic pain and improving health-related quality of life, particularly for patients for whom cost has been a barrier to access. Further large-scale, controlled research is needed to validate these observations and to establish standardised clinical guidelines for the use of medical cannabis in opioid tapering protocols.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
